View in EDS

Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia.
Authors: Eid N; Pediatric Hematology/Oncology Fellowship Program, Children's Hospital of Michigan, Detroit, Michigan., Zhao J; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Thibodeau J; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, Michigan., Edwards H; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Li J; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Bao X; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Polin L; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Kushner J; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Dzinic SH; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., White K; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Buck SA; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan., Back JB; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.; Tumor Biology and Microenvironment Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan., Stemmer PM; Tumor Biology and Microenvironment Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Institute of Environmental Health Sciences and Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan., Lee M; Institute of Environmental Health Sciences and Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan., Kim S; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan., Taub JW; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan.; Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan., Ge Y; Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan.; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, Michigan.
Source: ASPET discovery [ASPET Discov] 2025; Vol. 1. Date of Electronic Publication: 2025 Sep 25.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918994891106676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 3050-5674 (Electronic) Linking ISSN: 30505674 NLM ISO Abbreviation: ASPET Discov Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:3050-5674
DOI:10.1016/j.aspetd.2025.100014